Gilgamesh Pharmaceuticals

About:

Gilgamesh Pharmaceuticals provides medicines for psychedelic, novel psychotropic drugs, depression, anxiety, and stress-related disorders.

Website: https://www.gilgameshpharmaceutical.com

Twitter/X: gilgameshrx

Top Investors: Alumni Ventures, Y Combinator, Bossanova Investimentos, Gaingels, Pioneer Fund

Description:

Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.

Total Funding Amount:

$82.6M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

New York, New York, United States

Founded Date:

2019-01-01

Contact Email:

Investors(AT)GilgameshPharmaceutical.com

Founders:

Andrew Kruegel, Dalibor Sames, Jeff Witkin, Jonathan Sporn, Mike Cunningham

Number of Employees:

11-50

Last Funding Date:

2024-03-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai